News
30 November 2017
CANTAB Mobile and CANTAB Insight are now TGA approved for Australian market
We’re delighted to announce that both CANTAB Mobile and CANTAB Insight medical devices, designed for the assessment of cognitive health in clinical practice, have been approved for marketing in Australia by the Therapeutic Goods Administration (TGA) (ARTG No. 294119).
Read on
28 November 2017
Cognition Kit wearable technology demonstrates high compliance among patients with major depressive disorder (MDD)
At the 2017 International CNS Summit in Boca Raton, Florida, we were pleased to release the positive results from a pilot study into the evaluation of cognition and mood using wearable technology in patients with MDD.
Read on
13 November 2017
Join us at the CNS Summit 2017
Cambridge Cognition are attending the Collaborating for Novel Solutions (CNS) Summit: 16th-19th November 2017.
Read on
8 November 2017
Hogrefe becomes exclusive distributor of CANTAB in Finland
We’re pleased to announce that Hogrefe Psykologien Kustannus Oy is now an exclusive distributor of CANTAB software products for use in Finland by academic researchers and healthcare professionals.
Read on
6 November 2017
Speech recognition and online assessments: the future for clinical trials in Alzheimer’s disease?
New data demonstrates possibility for speech recognition and online assessments to enhance clinical trials in Alzheimer’s disease.
Read on
12 September 2017
Award of funding to develop novel digital health system
A new system being developed by Cambridge Cognition with Innovate UK funding will provide a non-invasive, inexpensive means of accurately monitoring levels of pain by combining artificial intelligence technology and cognitive neuroscience.
